[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse PCSK2

Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, secretory vesicle. Secreted Note=Localized in the secretion granules.
Domain PF01483 Proprotein convertase P-domain
PF00082 Subtilase family
PF16470 Peptidase S8 pro-domain
Function

Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Responsible for the release of glucagon from proglucagon in pancreatic A cells.

> Gene Ontology
 
Biological Process GO:0010817 regulation of hormone levels
GO:0016485 protein processing
GO:0016486 peptide hormone processing
GO:0016540 protein autoprocessing
GO:0030070 insulin processing
GO:0034230 enkephalin processing
GO:0034231 islet amyloid polypeptide processing
GO:0042445 hormone metabolic process
GO:0051604 protein maturation
GO:1901142 insulin metabolic process
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0017171 serine hydrolase activity
Cellular Component GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030425 dendrite
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0044297 cell body
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-264876: Insulin processing
R-HSA-392499: Metabolism of proteins
R-HSA-2980736: Peptide hormone metabolism
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PCSK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PCSK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PCSK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9610.154
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8510.418
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0190.284
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5320.0133
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7910.119
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2090.363
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.3650.224
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0150.993
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.6280.112
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0270.944
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0270.964
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0230.939
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PCSK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PCSK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PCSK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PCSK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PCSK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PCSK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PCSK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPCSK2
Nameproprotein convertase subtilisin/kexin type 2
Aliases SPC2; neuroendocrine convertase 2; KEX2-like endoprotease 2; NEC2; NEC 2; NEC-2; prohormone convertase 2; Pr ......
Chromosomal Location20p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PCSK2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PCSK2.
ID Name Drug Type Targets #Targets
DB00030Insulin HumanBiotechCPE, CTSD, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV, PCSK1, PCSK2, RB1, ......12
DB00071Insulin PorkBiotechCPE, CTSD, HLA-DQA2, HLA-DQB1, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV ......14